

1 **Title:** Socioeconomic and temporal heterogeneity in SARS-CoV-2 exposure and disease in
2 England from May 2020 to February 2023

3 **Authors:** Christian Morgenstern^{1, #}, Thomas Rawson¹, Wes Hinsley¹, Pablo N. Perez
4 Guzman¹, Samir Bhatt^{1,2, *}, Neil M. Ferguson^{1, *}

5 **Affiliations:**

6 ¹MRC Centre for Global Infectious Disease Analysis, Jameel Institute, School of Public
7 Health, Imperial College London, UK

8 ²University of Copenhagen, Denmark

9

10 *Contributed equally

11 #Corresponding author: c.morgenstern@imperial.ac.uk

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

34 **Abstract**

35 **Background:** The COVID-19 pandemic had resulted in over 20.5 million confirmed cases and
36 175,000 deaths in England by December 2023. The pandemic's impact varied significantly across
37 different population groups, influenced by deprivation, ethnicity, and policy measures.

38 **Methods:** We analysed individual-level data on SARS-CoV-2 testing, hospitalisations, deaths, and
39 vaccination records in England from May 2020 to February 2022. We used Poisson regression models
40 to estimate incidence rate ratios (IRRs) for first pillar 2 PCR positive cases, associated
41 hospitalisations, and deaths, adjusting for sex, ethnicity, deprivation, geographic region, age, and
42 epidemiological week. Model selection was based on cross-validation and performance metrics (AIC,
43 R^2).

44 **Findings:** The data analysed included 12,310,485 first SARS-CoV-2 pillar 2 PCR-confirmed
45 infections, 79,315 hospitalisations, and 107,823 deaths associated with the first SARS-CoV-2
46 infection. Significant differences were observed across IMD quintiles, with the most deprived areas
47 showing higher incidence rate ratios (IRRs) for death (1.64, 95% CI: 1.60-1.67) and hospitalisation
48 (1.80, 95% CI: 1.75-1.85) compared to the least deprived areas as the reference group for the entire
49 study period. Ethnic disparities were also notable, with higher IRRs for death and hospitalisation for
50 all non-White ethnicities relative to White ethnicities as the reference group. We note that the
51 magnitude of IRRs, for both deprivation and ethnicities, declined from the wild-type to the omicron
52 periods for severe outcomes. For cases, we observed IRRs above one for non-White ethnicities
53 during the wild-type and alpha periods only. Vaccine effectiveness (VE) was also assessed, with
54 models indicating a significant reduction in risk post-vaccination across all outcomes of interest.

55 **Interpretation:** Deprivation and ethnicity significantly influenced COVID-19 outcomes in England.
56 For severe outcomes, pre-existing health inequalities lead to large and persistent disparities. For
57 infections, both protective and support measures need to be structured with ethnicity and deprivation
58 in mind in the early parts of a pandemic.

59 **Funding:** UK Medical Research Council, Schmidt Foundation, National Institute of Health Research,
60 Community Jameel.

61 **Keywords:** SARS-CoV-2, risk factors, deprivation, ethnicity, vaccine effectiveness.

62

63

64

65

66

67 **Research in Context**

68 **Evidence before this study**

69 The COVID-19 pandemic has significantly impacted global health, and previous research has
70 highlighted the role of socioeconomic factors, such as deprivation and ethnicity, in influencing
71 outcomes. McGowan et al. found in a scoping review that 91% of studies showed significantly
72 higher COVID-19 mortality in areas of social disadvantage relative to more affluent areas. A
73 systematic review by Pan et al. ² showed the impact of ethnicity on clinical outcomes in COVID-
74 19. However, the impact of deprivation and ethnicity over different time periods of the COVID-
75 19 pandemic and its interplay with public health measures is poorly understood.

76 **Added value of this study**

77 This study leverages extensive data from multiple sources, including PCR-confirmed COVID-19
78 cases, hospitalisation records, death registries, and vaccination databases, to comprehensively
79 analyse COVID-19 outcomes in relation to deprivation and ethnicity across England. Using
80 Poisson regression, we provide estimates of incidence rate ratios (IRR) associated with different
81 levels of deprivation and ethnic backgrounds. This study also incorporates data on periods defined
82 by dominant variants and public health measures, allowing for a more detailed examination of how
83 these factors interact with local socioeconomic contexts to influence health outcomes.

84 **Implications of all the available evidence**

85 The findings underscore the importance of considering disparities in COVID-19 outcomes by
86 deprivation and ethnicity and highlight the need for targeted strategies to address these inequalities.
87 Policymakers should prioritise resource allocation and tailored interventions in high-risk areas to
88 mitigate the adverse impacts of the pandemic. Furthermore, the effectiveness of vaccination
89 programs should be continuously evaluated in the context of these socioeconomic determinants to
90 enhance their efficacy and reach. This research contributes to the growing body of evidence
91 supporting the need for an equitable public health response that addresses the specific needs of
92 diverse populations across different localities before the pandemic by reducing health inequalities
93 and in the pandemic response.

94

95

96

97

98

99

100

101 Introduction

102 By December 2023, the COVID-19 pandemic had caused over 20.5 million confirmed cases and over
103 175,000 deaths in England ^{3,4}. The pandemic did not impact individuals equally; individual-based
104 studies have explored the links between deprivation, ethnicity, and other factors on health outcomes to
105 varying levels ^{1,2,5-8}.

106 Past studies have explored heterogeneity in risk in England ⁹ and Scotland ¹⁰ using the Index of Multiple
107 Deprivation (IMD) ¹¹ at the Lower-Tier Local Authority (LTLA) level. LTLAs are areas where local
108 government provides services, and the UK Office of National Statistics (ONS) provides an extensive
109 set of data, including population age distribution, ethnicity, and measures of deprivation. These
110 measures vary substantially across LTLAs, as did the number of infections, hospitalisations, and deaths
111 reported across England over the course of the pandemic (Figure 1). We aim to understand
112 heterogeneity in COVID-19 outcomes and how this evolved to help inform policy planning ^{3,12,13}.

113 SARS-CoV-2 testing in England ¹⁴ had four “pillars”: hospital testing for health and care workers and
114 individuals with clinical needs (pillar 1), freely available testing for the general population (pillar 2),
115 serology (pillar 3) and targeted surveillance (pillar 4). Pillar 2 testing increased significantly from 10th
116 May 2020, and most testing was halted on 27th February 2022 with the introduction of the ‘Living with
117 COVID’ strategy ¹⁵. Several public health measures were introduced over this period, including stay-
118 at-home orders (see SI B.5) ^{3,13} at local and national levels.

119 We additionally investigate vaccine effectiveness (VE) in the post-vaccination period and the impact
120 of vaccination on risk heterogeneity. The SARS-CoV-2 immunisation programme in England was one
121 of the most rapid globally, with 89.9% of the adult population aged 20 or over receiving at least one
122 dose and 86.6% receiving at least two doses by 27th February 2022 ¹⁶. Test-negative case-control studies
123 (TNCCs) were the standard epidemiological tool for evaluating SARS-CoV-2 VE during the pandemic
124 ¹⁷⁻¹⁹, though TNCCs can potentially suffer from biases ²⁰. The main alternative to TNCCs used for VE
125 estimation during the COVID-19 pandemic is large population observational cohort studies that use
126 individual-level healthcare and surveillance data linked to vaccination status ²¹⁻²⁴.

127

128

[Figure 1]

129

130

131

132

133

134

135

136

137 **Methods**

138 **Data sources**

139 The UK Health Security Agency (UKHSA) maintains a single unified database of all SARS-CoV-2
140 positive test results in the country, categorised by pillar. The resulting database contains a hashed
141 version of a unique identifier (NHS number), the age, sex, ethnic group, home LTLA, symptom status,
142 testing pillar, and date of specimen for each positive case.

143 Second, linked to the case database by (hashed) National Health Service (NHS) number, UKHSA
144 maintains a database of all deaths within 28 days of a positive PCR test for SARS-CoV-2. This database
145 records the date of death, the date of hospital admission, and how the death was identified (e.g., via
146 hospital reporting, death registration, or both).

147 Third, two NHS data sources on hospitalisation were also linked by NHS number to the case database:
148 the Secondary Uses Service (SUS) data on hospital episodes and the Emergency Care Data Set (ECDS)
149 on attendance at Accident and Emergency departments.

150 Lastly, England maintains a national vaccination register, the National Immunisation Management
151 System (NIMS)¹⁶. Every SARS-CoV-2 vaccine dose given in England is recorded at the time of vaccine
152 administration. The anonymised version of the dataset used here contained a unique identifier (hashed
153 NHS number), age, sex, ethnic group, LTLA and administration date.

154 We extracted data from the versions of these databases with data up to 25th July 2023. Cases with a
155 valid NHS number were then linked to the NIMS vaccination dataset. Where a match was found, the
156 case was classified as having received a vaccine (either before or after testing positive). Cases with no
157 matching immunisation record were classified as having not been vaccinated.

158 Population denominator data was used to calculate the number of people who have neither received a
159 vaccine nor been diagnosed with SARS-CoV-2 infection. We used the 2021 Census population
160 estimates generated by the ONS²⁵, stratified by age, sex and LTLA²⁶. We made the simplifying
161 assumption that in the absence of COVID-19, the size of the English population and its age distribution
162 would have been at a steady state for our analysis period consistent with the Census 2021 estimates.
163 Individuals with missing information on sex, age, or residence location were not included in the
164 analysis.

165 We use the Index of Multiple Deprivation (IMD) dataset released in 2019¹¹ by the UK Ministry of
166 Housing, Local Communities, and Local Government, aggregated at the LTLA level and its
167 subcomponents (SI B.4).

168

169

170 **Statistical Analysis**

171 Survival models were used to estimate Incidence Rate Ratios (IRR), an estimate of the increased risk
172 of a particular outcome for a specific population group relative to a reference group. We used Poisson
173 regression using an offset to adjust for person-days at risk to generate IRRs for the different strata of
174 interest, proving a good approximation to continuous time survival models (see SI A)²⁷. Poisson
175 regressions are more general than Cox proportional hazard survival models, allowing for non-
176 proportional hazards. We investigated using negative binomial regressions to account for
177 overdispersion. We parametrically captured variation by systematically examining evidence for
178 interactions between covariates. We conducted model selection to identify the model which performed
179 best across all three outcomes of interest (infection, hospitalisation, and deaths) by considering the
180 average Akaike's information criterion (AIC) and coefficient of determination (R^2)^{28,29} across the three
181 respective models.

182 We included terms for sex, ethnic group, vaccination status and IMD in all models. We used a
183 categorical IMD variable, ranking LTLAs by average IMD score and then binning them into quintiles
184 (1 being least deprived, five being most). The three other covariates included in all models were
185 geographic region (either upper tier local authority or region), age (in 10-year bands with the last band
186 being 85+ or 10-year bands with all individuals below 40 grouped and a max-age of 80+) and
187 epidemiological week. We examined all pairwise interactions between these three variables. The level
188 of public health and social measures was computed from ONS LTLA restriction level data and the
189 Oxford COVID-19 Government Response Tracker³ and used as a parametric covariate (see SI Section
190 A and C.4) as restriction levels changed several times, creating non-continuous time intervals.

191 All survival analyses used the test specimen date as the outcome event date. Three SARS-CoV-2-related
192 events were defined: death within 28 days of any positive PCR test, hospitalisation where the individual
193 hospitalised tested PCR-positive between 14 days before admission and the day before discharge, and
194 any PCR-confirmed infection within pillar 2. We only consider the first SARS-CoV-2 infection for all
195 three events and associated hospitalisations and deaths.

196 We fitted the model for all three outcomes of interest. Individuals were treated as censored after a
197 positive SARS-CoV-2 pillar 2 PCR test to exclude post-primary infections and avoid bias since the UK
198 vaccination programme excluded people from being vaccinated within 28 days of a positive test.

199 Since the UKHSA/NHS and ONS data used different ethnicity categories, we aggregated ethnicities
200 into six groups that could be identified consistently across all datasets: White, South Asian, Asian
201 (other), Black, and Mixed/Other to be consistent across the two datasets (SI B.1). Details are provided
202 in Supplementary Information (SI B.1). The computation of age for each individual is outlined in the
203 SI B.2.

204 We estimated VE accounting for the type of vaccine (mRNA or adenovirus-based), time since

205 vaccination, and outcome of interest (death, hospitalisation, Pillar 2 PCR positive case). Details are
206 provided in SI section B.3. By comparing currently vaccinated individuals against people who would
207 be vaccinated in the future, we controlled for potential differences in behaviour and exposure risk
208 between those who are never vaccinated and those who eventually are. Censoring after the first recorded
209 positive test partially mitigated estimates from being affected by the accumulation of naturally acquired
210 immunity in the population.

211 To investigate how estimates varied over time, for example, in periods dominated by particular variants,
212 we restricted model fitting to data from the specific period of interest (censoring individuals with
213 positive tests before that period).

214 We used negative binomial regressions as a sensitivity analysis to explore over-dispersion in the count
215 data. In all figures, we display only results with a p-value of 0.05 or less.

216 All analyses were undertaken in R version 4.3.1 using the H2O.ai machine learning package version
217 3.42.0.2³⁰, which offers high-performance parallelised algorithms for fitting general linear models to
218 large datasets. A 32-core Intel-based server with 128GB RAM was used to conduct the analyses.

219

220 **Data access**

221 While all data used in this analysis were anonymised, the individual-level nature of the data used risks
222 individuals being identified or being able to self-identify if it is released publicly. Requests for access
223 to the underlying source data should be directed to UKHSA.

224

225 **Ethical approval**

226 Surveillance of COVID-19 testing and vaccination is undertaken under Regulation 3 of The Health
227 Service (Control of Patient Information) Regulations 2002 to collect confidential patient information
228 (www.legislation.gov.uk/uksi/2002/1438/regulation/3/made) under Sections 3(i) (a) to (c), 3(i)(d) (i)
229 and (ii) and 3(3). Data were shared with the investigators as part of the UK's emergency response to
230 the COVID-19 pandemic via the SPI-M subcommittee of the UK Scientific Advisory Group for
231 Emergencies (SAGE). Ethics permission was sought for the study via Imperial College London's
232 standard ethical review processes, and the study was approved by the College's Research Governance
233 and Integrity Team (ICREC reference: 21IC6945).

234

235 **Role of the funding source**

236 The funders of the study had no role in the study design, data collection, data analysis, data
237 interpretation, or writing of the report.

238

239 **Results**

240 We present the breakdown of the England population (56,427,863 people in England [Census 2021],
241 56,417,353 are in our synthetic population, and 56,344,410 are included in the analysis) in Table 1,
242 including the number of first episodes of SARS-CoV-2 infections (12,310,485) and associated
243 hospitalisations (79,315) or deaths (107,823) linked to that first infection from the week beginning 10th
244 May 2020 (isoweek 18) to 27th February 2022 (isoweek 8) confirmed by a pillar 2 PCR positive test.
245 These 95 weeks cover the full period for which population-wide testing was available.

246 [Table 1]

247 We examined a total of 360 model variants, which varied by the covariates and interactions included
248 (see SI A.2 for covariate definitions considered): age, definition of deprivation, regional disaggregation,
249 ethnicity disaggregation, and which interaction terms to include in the model. SI Table A.3–A.5 lists
250 the top 88 selected models for each outcome of interest. We found that less granular age categories had
251 better 10-fold cross-validation performance (under 40s, 10-year age bands up to 70, single group for
252 80+). Similarly, coarse spatial disaggregation (by NHS region of England) was favoured, and
253 deprivation was quantified by IMD quintiles. We chose ethnicity disaggregation into six groups as the
254 results were very close without a clear favoured disaggregation.

255 We compared the estimates from the preferred model against the data, and found a good qualitative fit
256 examining marginal IRRs (SI A.2).

257 We investigated the impact of overdispersion for each outcome of interest using negative binomial
258 regression models. For Pillar 2 PCR confirmed cases, we found a moderate level of overdispersion
259 ($k=0.33$) during the wild-type period. We found that either very high values of k (indicating marginal
260 overdispersion) or the Poisson model were preferred for all other periods. For hospitalisation and death
261 outcomes, the Poisson model was always preferred (SI section A and Table A.1).

262 Figure 2 presents the modelled IRRs for deprivation and ethnicity categories from the preferred model
263 for each endpoint and by period defined by variant dominance. IRRs for sex, age and region are
264 presented in SI Figure (D.12).

265 [Figure 2]

266 When we consider the entire period (May 2020-February 2022), the highest IMD quintile,
267 corresponding to the most deprived LTLAs, has an IRR (relative to the least deprived IMD quintile) of
268 1.64 (95% CI: 1.60-1.67) for death as the outcome, 1.80 (95% CI: 1.75-1.85) for hospitalisation, 1.02
269 (95% CI: 1.02-1.02) for a positive pillar 2 PCR test. For the Pillar 2 positive test outcome, we observed
270 significant differences between periods defined by variant dominance. The biggest differences were
271 observed for the Alpha variant with an IRR (for the highest quintile relative to the lowest) for that
272 endpoint of 1.45 (95% CI: 1.45-1.46).

273 For deaths, over the entire study period, South Asian ethnicity had an IRR 1.63 (95% CI: 1.59-1.68),
274 Asian (other) ethnicity an IRR 1.24 (95% CI: 1.17-1.32), and Black ethnicity an IRR 1.49 (95% CI:
275 1.43-1.54), with White ethnicity as the reference. For hospitalisation, over the entire study period, South
276 Asian ethnicity had an IRR 1.90 (95% CI: 1.84-1.96), Asian (other) ethnicity an IRR 1.38 (95% CI:
277 1.30-1.47), and Black ethnicity an IRR 1.61 (95% CI: 1.55-1.68). Using pillar 2 PCR positive tests as
278 the endpoint, over the entire study period, South Asian ethnicity had an IRR 0.89 (95% CI: 0.88-0.89),
279 Asian (other) ethnicity an IRR 0.78 (95% CI: 0.78-0.79), and Black ethnicity an IRR 0.89 (95% CI:
280 0.89-0.90). The IRRs for Mixed/Other ethnicity are reported in SI Table D.3.

281 Ethnicity differences declined for the Pillar 2 PCR positive test endpoint throughout the pandemic. IRR
282 for pillar 2 PCR positive cases declines for all non-White ethnicities (relative to White) over time, with
283 $IRR_{WT} > IRR_{Alpha} > IRR_{Delta}$. During the Omicron period, non-White IRRs were broadly similar to the
284 Delta period but typically slightly above IRR_{Delta} . For death and hospitalisation, we observed a declining
285 IRR over time for South Asian ethnicity, with IRR_{WT} , IRR_{Alpha} , and IRR_{Delta} exhibiting overlapping
286 confidence intervals but $IRR_{Omicron}$ statistically significantly lower. Other Asian ethnicities had high
287 IRRs (overlapping confidence intervals) for the WT and Alpha periods and significantly lower IRRs
288 for Delta and Omicron. Black ethnicities exhibited high IRRs throughout the entire period in the range
289 of 1.01-1.45 for death and 1.10-1.76 for hospitalisation.

290 Results for deprivation were consistent for severe outcomes (hospitalisation and death) throughout the
291 pandemic, with IRRs monotonically increasing as deprivation increased, but with IRRs during the
292 Omicron period lower than other periods. This result also applied to a more granular representation of
293 deprivation, using deciles (Figure D.12(A) in SI) and for the different subcomponents of the IMD
294 measure (SI section E.1-E.7). For Pillar 2 PCR positive cases, we observed an increasing IRR with
295 increasing deprivation for the WT and Alpha periods but not for the Delta and Omicron periods. This
296 resulted in the IRR for the whole period being close to 1. This result was consistent with IMD deciles
297 and the subcomponents of the IMD index.

298 [Figure 3]

299 In Figure 4 we present the VE results (SI section B.3 and Table D.2). We obtain a VE (defined as 1-
300 IRR) estimate for mRNA vaccines ranging from 86.8% (over 18 weeks after second dose, 95% CI:
301 86.2-87.3) to 97.1% (less than two weeks after booster dose, 95% CI: 96.6-97.6) for protection against
302 death for individuals with at least two doses, 90.1% (over 18 weeks after second dose, 95% CI: 89.5-
303 90.5) to 96.7% (2-10 weeks after booster dose, 95% CI: 96.5-97) against hospitalisation and 30.4%
304 (over 18 weeks after booster dose, 95% CI: 29.3-31.5) to 84.5% (2-10 weeks after second dose, 95%
305 CI: 84.4-84.6) against pillar 2 PCR positive confirmed infections for the full study period.

306 For adenovirus-based vaccines, we estimated VE for individuals with at least two doses, ranging from
307 77.2% (over 18 weeks after second dose, 95% CI: 76.2-78) to 95.9% (less than two weeks after booster

308 dose, 95% CI: 95.3-96.5) for protection against death, 84.3% (over 18 weeks after second dose, 95%
309 CI: 83.6-85) to 96.2% (2-10 weeks after booster dose, 95% CI: 95.9-96.5) against hospitalisation, and
310 29.6% (over 18 weeks after booster dose, 95% CI: 27.6-31.5) to 68.5% (2-10 weeks after second dose,
311 95% CI: 68.3-68.6) against pillar 2 PCR-positive confirmed infections for the full study period.

312 We found that VE was consistently lower for the Omicron period. There was little to no difference in
313 VE estimates for severe outcomes for the Alpha and Delta time periods.

314 We present the estimated VE results for all variants, vaccine status, and vaccine types in SI Table D.2
315 with their associated 95% CIs. The confidence intervals are narrow due to the large number of events
316 observed (Table 1B); confidence intervals are wider for the variant period-specific estimates.

317 [Figure 4]

318 Figure 4 shows the estimated IRRs for the restriction level covariate. We estimated the IRR for the full
319 time period of 1.14 (95% CI: 1.12-1.15) for deaths, 1.13 (95% CI: 1.12-1.15) for hospitalisation, and
320 1.17 (95% CI: 1.17-1.17) for Pillar 2 PCR positive cases. The estimated IRR for restriction level for the
321 WT and Alpha periods was lower for deaths and hospitalisation. However, for Pillar 2 PCR positive
322 cases, we found that the IRR for restriction level was higher during the WT period and lower for the
323 Alpha period (Figure 4). The IRRs for the Delta period are one, as no substantial restrictions were in
324 place at that time.

325

326 Discussion

327 We considered the impact of sex, age, region, deprivation, level of restrictions, and ethnicity on the
328 relative risk of a SARS-CoV-2 pillar 2 PCR-positive first infection, hospitalisation, or death. Our
329 proposed model was selected to provide a good fit across all three outcomes of interest. Our results
330 extend previous work on the impact of deprivation ¹ and evidence risk heterogeneity by ethnicity in
331 England ⁶⁻⁸ and globally ².

332 We find that modelling overdispersion for pillar 2 PCR positive cases was necessary for the wild-type
333 period, consistent with Morrissey et al. ¹², and the value for the overdispersion we find aligns with other
334 estimates outside China ^{31,32}. We did not find overdispersion to be present for severe outcomes, and the
335 Poisson model provides the best fit to the data. Even though pillar 2 PCR tests were available widely,
336 this indicates that some groups, defined by higher levels of deprivation or non-White ethnicity, may
337 have accessed testing less, leading to the observed overdispersion. This was less likely to be the case
338 for more severe outcomes as testing would be more likely conducted due to the more severe nature of
339 the infection.

340 The differences in IRRs we observe by outcome (infection, hospitalisation, or death) indicate a
341 difference between severe outcomes and infections. For severe outcomes, we observed a significant

342 risk heterogeneity by age, with older age groups at higher risks than younger age groups at an
343 exponential rate (Figure SI D.10(B)) consistent with the variation of the infection fatality ratio by age
344 in the pre-vaccination era³³. Increased risk is also positively associated with higher levels of deprivation
345 (Figure 3A), and the difference between the most deprived quintile of LTLAs and the least deprived
346 quintile is significant for all periods considered. Similarly, we find that non-White ethnicities are at
347 increased risk. For pillar 2 PCR-positive cases, the picture is more nuanced. The risk by age is driven
348 by contact patterns, as defined by the average number of contacts per person (SI Figure C.6) for the
349 different age groups. We observed that the difference in risk between age groups was on a similar scale
350 compared to the large differences we observed for severe outcomes. We saw similar risk heterogeneity
351 patterns for both deprivation and ethnicity but less strongly than for severe outcomes. The results for
352 pillar 2 PCR-positive cases were consistent with other studies³⁴ and that individuals exhibit self-
353 protective behaviours³⁵.

354 For severe outcomes, we observed less variation throughout the pandemic, pointing to existing health
355 inequalities driving the strong association between deprivation, ethnicity, and risk of severe outcomes.
356 This held consistently for all sub-components of the index of multiple deprivation, except for the Living
357 Environment component, and particularly strongly for the Income, Employment, Health, and Education
358 sub-components (Figure SI sections E.1-E.7). This observation is consistent with known socio-
359 economic and ethnic disparities in the UK for type-2 diabetes³⁶, which is a known risk factor for SARS-
360 CoV-2 infections. Interestingly, we observed a high IRR for South Asian ethnicity, for both severe
361 outcomes and infections, which reduced over time (Figure 3.B), pointing to the metabolic component
362 impacting outcomes being reduced for omicron and delta as individuals of South Asian ethnicity are at
363 higher risk of metabolic disease³⁷.

364 We assessed vaccine effectiveness, and our results broadly align with previously published VE
365 estimates for England by UKHSA¹⁷ for similar periods and VE definitions. We find vaccine
366 effectiveness for the mRNA vaccines is consistent with UKHSA estimates of 88.0% (95% CI: 85.3-
367 90.1) for two doses of BNT162b2 for infections for persons with the Delta variant. Similarly, we find
368 vaccine effectiveness for the adenovirus vaccines is in line with UKHSA estimates of 67.0% (95% CI:
369 61.3-71.8) for persons with two doses of the ChAdOx1 nCoV-19 vaccine. For the Omicron variant,
370 estimates vary more widely³⁸ with VE against hospitalisation, ranging from 89.6% to 95.3 compared
371 to 67.8% to 92.4% from the literature. Similarly, VE against pillar 2 PCR confirmed infection ranged
372 from 17% to 69.5% compared to 11.7% to 75.3% in the literature. We note that we only consider first
373 infections for the Omicron period, which may bias our VE estimates to be higher.

374 The policy implications of our study are that both protective and support measures need to be structured
375 with ethnicity and deprivation in mind, particularly in the early stages of a pandemic. Deprivation had
376 a particularly significant impact during the Alpha variant era for infections, and for ethnicity, we
377 observed a reduction of IRRs as the pandemic progressed (Figure 3). This suggests that more deprived

378 areas were less able to isolate effectively, potentially due to work, during heightened restrictions. Ethnic
379 minorities, in particular Bangladeshi and Pakistani men, worked in occupations directly impacted by
380 lockdown measures, and more broadly, ethnic minorities had less access to savings³⁹, potentially
381 exposing them to a higher risk of community transmission.

382 Considering different levels of restrictions, we found IRRs for infections and severe outcomes in the
383 wild-type and Alpha periods to be above one. This highlights the impact of the different timing of
384 restrictions between regions, as we already account for week and region effects in the model. We note
385 that other results were not sensitive to whether restrictions were included as a predictor in the model.

386 A limitation is that we only considered first infections in this study and could not make any statements
387 about reinfections. However, we note that up to November 2021, with the arrival of the Omicron variant
388 of SARS-CoV-2, we have observed predominantly first infections. We only quantify the incidence
389 among those seeking tests, not the underlying infection incidence. This limits our ability to model the
390 impact of comorbidities, such as obesity⁴⁰, as we cannot differentiate if the outcome is worse due to
391 pre-existing comorbidities or those groups being more exposed.

392 Future research priorities include a multi-outcome survival model to incorporate infections and severe
393 outcomes in the same model. Integrating serology and infection prevalence data is essential in
394 addressing questions such as the impact of pre-existing comorbidities on the risk heterogeneity by
395 ethnicity or socio-economic group.

396

397

398

399 **Declarations**

400 **Funding** All authors acknowledge funding from the Medical Research Council (MRC) Centre for Global
401 Infectious Disease Analysis (MR/X020258/1) funded by the UK MRC and carried out in the frame of the Global
402 Health EDCTP3 Joint Undertaking supported by the EU; the NIHR for support for the Health Research Protection
403 Unit in Modelling and Health Economics, a partnership between the UK Health Security Agency (UKHSA),
404 Imperial College London, and London School of Hygiene & Tropical Medicine (grant code NIHR200908); a
405 philanthropic donation from Community Jameel supporting the work of the Jameel Institute S.B. acknowledges
406 support from the Novo Nordisk Foundation via The Novo Nordisk Young Investigator Award
407 (NNF20OC0059309). SB acknowledges the Danish National Research Foundation (DNRF160) through the chair
408 grant. S.B. acknowledges support from The Eric and Wendy Schmidt Fund for Strategic Innovation via the
409 Schmidt Polymath Award (G-22-63345), which also supports C.M. The funders of the study had no role in the
410 study design, data collection, data analysis, data interpretation, or writing of the report. For the purpose of open
411 access, the author has applied a 'Creative Commons Attribution' (CC BY) licence to any Author Accepted
412 Manuscript version arising from this submission.

413 **Availability of data and materials** While all data used in this analysis were anonymised, the individual-level
414 nature of the data used risks individuals being identified or being able to self-identify if it is released publicly.
415 Requests for access to the underlying source data should be directed to UKHSA.

416

417 **Code availability** https://github.com/cm401/covid19_risk_heterogeneity_england

418 **Competing interests.** The authors declare no competing interests.

419 **Authors' Contributions** NMF, CM, and SB conceptualised the study. CM, WH, PPG, and NMF curated and
420 validated the data. CM formally analysed and visualised the data. SB and NMF acquired funding and supervised
421 the study. CM wrote the original manuscript draft. All authors were responsible for the methodology and review
422 and editing of the manuscript. All authors discussed, edited, and approved the final version of the manuscript. All
423 authors had final responsibility for the decision to submit the manuscript for publication.

424

425

426 **References**

- 427 1 McGowan VJ, Bambra C. COVID-19 mortality and deprivation: pandemic, syndemic, and endemic
428 health inequalities. *Lancet Public Health* 2022; **7**: e966–75.
- 429 2 Pan D, Sze S, Minhas JS, *et al.* The impact of ethnicity on clinical outcomes in COVID-19: A
430 systematic review. *EClinicalMedicine* 2020; **23**: 100404.
- 431 3 Hale T, Angrist N, Goldszmidt R, *et al.* A global panel database of pandemic policies (Oxford
432 COVID-19 Government Response Tracker). *Nat Hum Behav* 2021; **5**: 529–38.
- 433 4 Phillips T. A global panel database of pandemic policies (Oxford COVID-19 Government Response
434 Tracker). <https://github.com/OxCGRT/covid-policy-dataset>.
- 435 5 Kontopantelis E, Mamas MA, Webb RT, *et al.* Excess deaths from COVID-19 and other causes by
436 region, neighbourhood deprivation level and place of death during the first 30 weeks of the pandemic
437 in England and Wales: A retrospective registry study. *Lancet Reg Health - Eur* 2021; **7**: 100144.
- 438 6 Ward H, Atchison C, Whitaker M, *et al.* SARS-CoV-2 antibody prevalence in England following
439 the first peak of the pandemic. *Nat Commun* 2021; **12**: 905.
- 440 7 Lo C-H, Nguyen LH, Drew DA, *et al.* Race, ethnicity, community-level socioeconomic factors, and
441 risk of COVID-19 in the United States and the United Kingdom. *eClinicalMedicine* 2021; **38**:
442 101029.
- 443 8 Mathur R, Rentsch CT, Morton CE, *et al.* Ethnic differences in SARS-CoV-2 infection and COVID-
444 19-related hospitalisation, intensive care unit admission, and death in 17 million adults in England:
445 an observational cohort study using the OpenSAFELY platform. *The Lancet* 2021; **397**: 1711–24.
- 446 9 Padellini T, Jersakova R, Diggle PJ, *et al.* Time varying association between deprivation, ethnicity
447 and SARS-CoV-2 infections in England: A population-based ecological study. *Lancet Reg Health -
448 Eur* 2022; **15**: 100322.
- 449 10 Wood AJ, Sanchez AR, Bessell PR, Wightman R, Kao RR. Assessing the importance of
450 demographic risk factors across two waves of SARS-CoV-2 using fine-scale case data. *PLOS
451 Comput Biol* 2023; **19**: e1011611.
- 452 11 UK Ministry of Housing, Communities and Local Government. The English Indices of Deprivation
453 2019. 2019; published online Sept 26.
454 [https://assets.publishing.service.gov.uk/media/5d8e26f6ed915d5570c6cc55/IoD2019_Statistical_R
455 elease.pdf](https://assets.publishing.service.gov.uk/media/5d8e26f6ed915d5570c6cc55/IoD2019_Statistical_Release.pdf).

- 456 12 Morrissey K, Spooner F, Salter J, Shaddick G. Area level deprivation and monthly COVID-19 cases:
457 The impact of government policy in England. *Soc Sci Med* 2021; **289**: 114413.
- 458 13 Phillips T. Oxford Covid-19 Government Response Tracker (OxCGRT), Blavatnik School of
459 Government, University of Oxford. <https://github.com/OxCGRT/covid-policy-tracker>.
- 460 14 Department of Health and Social Care. Coronavirus (COVID-19): scaling up testing programmes.
461 2020 [https://assets.publishing.service.gov.uk/media/5e888f05e90e0707799498b3/coronavirus-](https://assets.publishing.service.gov.uk/media/5e888f05e90e0707799498b3/coronavirus-covid-19-testing-strategy.pdf)
462 [covid-19-testing-strategy.pdf](https://assets.publishing.service.gov.uk/media/5e888f05e90e0707799498b3/coronavirus-covid-19-testing-strategy.pdf).
- 463 15 UK Health Security Agency. Testing Times: striving for quality in the COVID-19 national testing
464 service, April 2020 to March 2022. [https://www.gov.uk/government/publications/coronavirus-](https://www.gov.uk/government/publications/coronavirus-covid-19-scaling-up-testing-programmes)
465 [covid-19-scaling-up-testing-programmes](https://www.gov.uk/government/publications/coronavirus-covid-19-scaling-up-testing-programmes).
- 466 16 NHS England. National vaccination programmes. [https://www.england.nhs.uk/contact-us/privacy-](https://www.england.nhs.uk/contact-us/privacy-notice/national-flu-vaccination-programme/)
467 [notice/national-flu-vaccination-programme/](https://www.england.nhs.uk/contact-us/privacy-notice/national-flu-vaccination-programme/).
- 468 17 Lopez Bernal J, Andrews N, Gower C, *et al*. Effectiveness of Covid-19 Vaccines against the
469 B.1.617.2 (Delta) Variant. *N Engl J Med* 2021; **385**: 585–94.
- 470 18 Lopez Bernal J, Andrews N, Gower C, *et al*. Effectiveness of the Pfizer-BioNTech and Oxford-
471 AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older
472 adults in England: test negative case-control study. *BMJ* 2021; : n1088.
- 473 19 Chua H, Feng S, Lewnard JA, *et al*. The Use of Test-negative Controls to Monitor Vaccine
474 Effectiveness: A Systematic Review of Methodology. *Epidemiology* 2020; **31**: 43–64.
- 475 20 WHO. Evaluation of COVID-19 vaccine effectiveness: interim guidance, 17 March 2021. 2021
476 <https://iris.who.int/handle/10665/340301>.
- 477 21 Bar-On YM, Goldberg Y, Mandel M, *et al*. Protection of BNT162b2 Vaccine Booster against Covid-
478 19 in Israel. *N Engl J Med* 2021; **385**: 1393–400.
- 479 22 Chemaitelly H, Yassine HM, Benslimane FM, *et al*. mRNA-1273 COVID-19 vaccine effectiveness
480 against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. *Nat Med* 2021; **27**:
481 1614–21.
- 482 23 Vasileiou E, Simpson CR, Shi T, *et al*. Interim findings from first-dose mass COVID-19 vaccination
483 roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. *The*
484 *Lancet* 2021; **397**: 1646–57.
- 485 24 Nafilyan V, Bermingham CR, Ward IL, *et al*. Risk of death following COVID-19 vaccination or
486 positive SARS-CoV-2 test in young people in England. *Nat Commun* 2023; **14**: 1541.
- 487 25 ONS. Census. <https://www.ons.gov.uk/census>.
- 488 26 Office of National Statistics. Office of National Statistics Census 2021 Create a custom dataset.
489 <https://www.ons.gov.uk/datasets/create>.
- 490 27 Laird N, Olivier D. Covariance Analysis of Censored Survival Data Using Log-Linear Analysis
491 Techniques. *J Am Stat Assoc* 1981; **76**: 231–40.
- 492 28 Stoica P, Selen Y. Model-order selection. *IEEE Signal Process Mag* 2004; **21**: 36–47.
- 493 29 Kvalseth TO. Cautionary Note about R 2. *Am Stat* 1985; **39**: 279.

- 494 30 H2O. H2O.ai. h2o: R Interface for H2O. R package version 3.42.0.2 2023.
495 <https://github.com/h2oai/h2o-3>.
- 496 31 Endo A, Centre for the Mathematical Modelling of Infectious Diseases COVID-19 Working Group,
497 Abbott S, Kucharski AJ, Funk S. Estimating the overdispersion in COVID-19 transmission using
498 outbreak sizes outside China. *Wellcome Open Res* 2020; **5**: 67.
- 499 32 Hodcroft EB, Wohlfender MS, Neher RA, Riou J, Althaus CL. Estimating R_e and overdispersion
500 in secondary cases from the size of identical sequence clusters of SARS-CoV-2. 2024; published
501 online May 27. DOI:10.1101/2024.05.26.24307940.
- 502 33 COVID-19 Forecasting Team. Variation in the COVID-19 infection–fatality ratio by age, time, and
503 geography during the pre-vaccine era: a systematic analysis. *The Lancet* 2022; **399**: 1469–88.
- 504 34 Rawson T, Hinsley W, Sonabend R, Semenova E, Cori A, Ferguson NM. The impact of health
505 inequity on spatial variation of COVID-19 transmission in England. *PLOS Comput Biol* 2024; **20**:
506 e1012141.
- 507 35 Papageorge NW, Zahn MV, Belot M, *et al.* Socio-demographic factors associated with self-
508 protecting behavior during the Covid-19 pandemic. *J Popul Econ* 2021; **34**: 691–738.
- 509 36 Nagar SD, Nápoles AM, Jordan IK, Mariño-Ramírez L. Socioeconomic deprivation and genetic
510 ancestry interact to modify type 2 diabetes ethnic disparities in the United Kingdom.
511 *eClinicalMedicine* 2021; **37**: 100960.
- 512 37 Ramachandran A. Trends in prevalence of diabetes in Asian countries. *World J Diabetes* 2012; **3**:
513 110.
- 514 38 Stowe J, Andrews N, Kirsebom F, Ramsay M, Bernal JL. Effectiveness of COVID-19 vaccines
515 against Omicron and Delta hospitalisation, a test negative case-control study. *Nat Commun* 2022;
516 **13**: 5736.
- 517 39 Platt L, Warwick R. COVID-19 and Ethnic Inequalities in England and Wales *. *Fisc Stud* 2020; **41**:
518 259–89.
- 519 40 Yates T, Summerfield A, Razieh C, *et al.* A population-based cohort study of obesity, ethnicity and
520 COVID-19 mortality in 12.6 million adults in England. *Nat Commun* 2022; **13**: 624.

521


522

523

524

525

526



527

528 **Figure 1: Maps of the population of England at the LTLA level between 10 May 2020 – 27 February 2022. (A) Index**
529 **of Multiple Deprivation quintile by LTLA, (B) percentage of non-White population by LTLA, (C) percentage of**
530 **individuals vaccinated with at least two doses for all ages, (D) percentage of positive Pillar 2 PCR confirmed first**
531 **cases by LTLA, (E) percentage of hospitalisation by LTLA, (F) percentage deaths by LTLA**

532 **A**

Variable	Category	n	Person days at risk	Cases (Pillar 2 PCR)	Hospitalisations	Deaths
Sex	Female	28,685,081	17,345,400,702	6,517,293	32,884	49,389
	Male	27,659,329	16,807,116,305	5,793,192	46,431	58,434
Age	under_40	28,863,746	17,378,043,704	7,986,079	951	1,246
	40_49	7,126,246	4,298,749,448	1,832,839	1,909	2,211
	50_59	7,574,556	4,665,987,550	1,400,202	5,251	5,989
	60_69	5,734,391	3,547,069,498	635,915	11,240	12,753
	70_79	4,559,170	2,762,316,669	284,970	21,571	26,508
	above_80	2,486,301	1,500,350,138	170,480	38,393	59,116
Region	East Midlands	4,842,841	2,923,964,911	1,086,738	7,759	10,572
	East of England	6,278,538	3,821,826,715	1,296,183	8,816	12,411
	London	8,837,013	5,309,194,394	1,937,334	10,494	12,285
	North East	2,651,524	1,599,576,314	638,786	4,244	6,407
	North West	7,420,784	4,455,050,061	1,849,257	14,878	19,004
	South East	9,264,652	5,678,938,650	1,890,892	10,965	16,179
	South West	5,680,938	3,491,446,658	1,050,950	4,586	7,439
	West Midlands	5,894,953	3,564,918,434	1,296,108	9,891	12,840
Yorkshire and The Humber	5,473,167	3,307,600,870	1,264,237	7,682	10,686	
IMD Quintile	IMD1	7,674,923	4,699,769,599	1,569,158	7,821	11,696
	IMD2	9,445,584	5,762,949,346	1,921,063	11,564	16,629
	IMD3	10,876,412	6,615,134,330	2,302,369	15,088	20,659
	IMD4	11,801,363	7,137,336,955	2,586,990	16,830	22,278
	IMD5	16,546,128	9,937,326,777	3,930,905	28,012	36,561
Ethnicity	Asian (other)	1,548,640	913,540,586	322,769	1,101	1,209
	Black	2,307,809	1,356,279,568	601,101	2,688	3,152
	Mixed/Other	2,698,916	1,643,470,031	395,571	1,012	1,143
	South Asian	4,058,419	2,381,064,042	984,164	4,955	5,381
	White	45,730,626	27,858,162,780	10,006,880	69,559	96,938

533

534

535 **B**


Variable	Category	n	Person days at risk	Cases (Pillar 2 PCR)	Hospitalisations	Deaths
Vaccination status	Not Vaccinated	12,524,706	21,652,863,421	7,030,900	59,942	80,601
	Over 3w after first dose Adenovirus	343,341	1,168,792,975	97,771	922	2,419
	Over 18w after second dose Adenovirus	2,781,388	1,561,139,076	1,068,220	4,299	5,879
	2-10w after booster dose >2w Adenovirus	7,434,225	772,914,618	428,088	806	966
	10-18w after booster dose Adenovirus	9,188,109	332,906,007	137,555	931	1,522
	Over 18w after booster dose Adenovirus	508,392	12,907,790	5,238	51	148
	Less than 3w after first dose mRNA	253,760	438,532,528	210,475	2,010	2,364
	Over 3w after first dose mRNA	2,462,228	1,187,931,423	542,990	1,081	2,388
	Less than 2w after second dose mRNA	331,407	234,175,466	47,748	66	66
	2-10w after second dose mRNA	1,206,396	829,053,400	113,626	78	132
	10-18w after second dose mRNA	967,000	919,526,650	373,924	492	398
	Over 18w after second dose mRNA	4,066,262	1,129,558,164	751,049	2,853	3,765
	Less than 2w after booster dose mRNA	301,068	178,424,050	168,635	227	151
	2-10w after booster dose mRNA	6,054,894	586,137,083	294,073	764	770
	10-18w after booster dose mRNA	5,512,367	326,242,322	207,494	1,279	1,809
	Over 18w booster dose mRNA	1,954,193	43,244,152	16,974	236	385

536

537


538 **Table 1: Population for England with numbers of first Pillar 2 PCR confirmed SARS-CoV-2, hospitalisations and**
 539 **deaths between 10th May 2020 and 27th February 2022. (A) Population breakdown by sex, age, region, deprivation,**
 540 **and ethnicity. (B) Breakdown by vaccination status for categories with more than 200,000 doses at the end of the**
 541 **study period (n is the count of individuals in this category at the end of the study period, person days at risk and**
 542 **counts of Pillar 2 PCR positive cases, hospitalisations and deaths are over the entire study period). Vaccination status**
 543 **categories are by vaccination type (Adenovirus or mRNA), vaccine dose, and time since vaccination. The whole table**
 544 **for panel B is available in SI Figure D.9.**

545



546


547 **Figure 2: Estimated IRRs for (A) deprivation and (B) ethnicity covariates from preferred models. Deprivation was**
 548 **categorised by quintiles of the Index of Multiple Deprivation score defined at the LTLA level (results for sub-**
 549 **components are available in the SI), with the first (least deprived) quintile (IMD1) being the reference group**
 550 **(IRR=1). Results are shown for the whole pandemic ('all' - test dates between May 2020 and February 2022) and for**
 551 **the time intervals within that period where specific viral variants dominated (see SI for details). WT=Wild-Type**
 552 **(pre-December 2020).**



553

554 **Figure 3: Vaccine effectiveness (VE=1-RR) for different vaccination statuses with not vaccinated as the reference**
 555 **group (IRR=1 / VE=0). Results are shown for the whole pandemic ('all' - test dates between May 2020 and February**
 556 **2022) and for the time intervals within that period where specific viral variants dominated (see SI for details). Results**
 557 **for the Second Dose and Booster Dose categories are displayed for mRNA and Adenovirus vaccines (all other results**
 558 **are in SI Table D.3 and Figure D.11). WT=Wild-Type (pre-December 2020).**

559



560

561 **Figure 4: Estimated IRRs for restriction levels. Results are shown for the whole pandemic ('all' - test dates**
562 **between May 2020 and February 2022) and for the time intervals within that period where specific viral variants**
563 **dominated (see SI for details). Restriction level is a numeric covariate in the model.**